Related Experiment Videos
Statins and the vasculopathy of systemic sclerosis: potential therapeutic agents?
Chris T Derk1, Sergio A Jimenez
1Division of Rheumatology, Department of Medicine, Thomas Jefferson University, 613 Curtis Bldg, 1015 Walnut Street, Philadelphia, PA 19107-5541, USA. Chris.Derk@jefferson.edu
Insights
Statins may offer a novel therapeutic approach for systemic sclerosis vasculopathy. Their pleiotropic effects, beyond lipid reduction, show potential in mitigating vascular injury and fibrosis in this condition.
Area of Science:
- Vascular Biology
- Rheumatology
- Pharmacology
Background:
- Endothelial cell injury initiates systemic sclerosis pathogenesis, leading to T-cell infiltration, cytokine release, and fibroblast activation.
- This process results in vascular fibrosis and excessive collagen deposition, characteristic of systemic sclerosis vasculopathy.
- Current treatments for systemic sclerosis vasculopathy are limited, focusing on vasodilation and antiplatelet aggregation, with few agents impacting vascular remodeling.
Purpose of the Study:
- To review the potential of statins in modifying the course of systemic sclerosis vasculopathy.
- To explore the pleiotropic, lipid-independent effects of statins relevant to vascular injury.
- To assess the emerging evidence for statins as a disease-modifying therapy in early-stage systemic sclerosis.
Main Methods:
- Literature review of recent studies on statin effects beyond lipid lowering.
- Analysis of research investigating mechanisms of vascular injury in systemic sclerosis.
- Evaluation of clinical and preclinical data on statins' impact on endothelial function and fibrosis.
Main Results:
- Statins exhibit numerous effects independent of lipid lowering, including anti-inflammatory and antioxidant properties.
- These pleiotropic effects suggest potential benefits in preventing vascular injury and ischemic events.
- Emerging evidence indicates statins may positively influence the vascular remodeling seen in systemic sclerosis.
Conclusions:
- Statins possess properties that may counteract the pathogenic mechanisms of systemic sclerosis vasculopathy.
- Their potential disease-modifying effects warrant further investigation, especially in early disease stages.
- Statins represent a promising therapeutic avenue for managing systemic sclerosis-associated vascular complications.
Abstract:
It has been postulated that endothelial cell injury is the initiating event in the pathogenesis of systemic sclerosis, causing attraction, attachment, migration and infiltration of activated T-cells and subsequent production of cytokines and growth factors. As a result of the action of these cytokines and growth factors, chemoattraction of fibroblasts into the vessel wall and transdifferentiation of resident fibroblasts and smooth muscle cells into myofibroblasts occur leading to fibrosis and exaggerated collagen deposition in the vessel wall. To date, the therapeutic options for the vasculopathy of systemic sclerosis have been limited to drugs that cause vasodilation and inhibit platelet aggregation and only a few agents have shown vascular remodeling effects. Therapeutic agents that could potentially modify the course of this vasculopathy may have a disease-modifying effect, particularly, if instituted in the early stages of the disease. Extensive recent studies have shown that statins display numerous effects independent of their well-established lipid-lowering effect that may be of potential benefit in preventing vascular injury and ischemic vascular events. Here, we review the current literature, which suggests that statins may have a modifying effect on the vasculopathy of systemic sclerosis.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Atherosclerosis III: Management
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:29Pharmacogenomics: Identification of New Drug Targets
01:23Atherosclerosis IV: Nursing Management
01:27Peripheral Artery Disease III: Interprofessional Care